Patisiran
- TRADE NAME: Onpattro (Alnylam Pharma Inc)
- INDICATIONS: indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
- CLASS: Small interfering RNA (siRNA), Transthyretin-directed small interfering RNA
- HALF-LIFE: 1.8–3.2 days
FDA APPROVAL DATE: 08/10/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
no available data
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric